Treatment of the dry form of age-related macular degeneration: the studied present and promising future

Q4 Medicine

Russian Journal of Clinical Ophthalmology Pub Date : 2022-01-01 DOI:10.32364/2311-7729-2022-22-4-240-246

N. G. Glazko, O.A. Kanaeva, M.H. Rabadanova

{"title":"Treatment of the dry form of age-related macular degeneration: the studied present and promising future","authors":"N. G. Glazko, O.A. Kanaeva, M.H. Rabadanova","doi":"10.32364/2311-7729-2022-22-4-240-246","DOIUrl":null,"url":null,"abstract":"Age-related macular degeneration (AMD) is the main cause of central vision loss in elder group of patients. At the same time, annually, the number of people with detected changes in the retina corresponding to different forms of macular dystrophy is steadily growing. The disease is considered to be a highly significant medical, social and economic problem, since a deterioration of the central vision negatively affects the life quality and work capacity of patients. The article presents an analysis of modern views concerning the current therapy possibilities for the dry form of AMD, including the use of nutraceuticals, consisting of lutein, zeaxanthin, mesoseaxanthin, as well as an overview of the directions of development and clinical trials. The use of lutein- and zeaxanthin-containing compounds can be recommended for prevention both the AMD progression and the presence of risk factors for its development, especially in persons over 50 years of age, as well as in the presence of high visual workload. Keywords: age-related macular degeneration, nutraceuticals, carotenoids, lutein, zeaxanthin, mesoseaxanthin. For citation: Glazko N.G., Kanaeva O.A., Rabadanova M.H. Treatment of the dry form of age-related macular degeneration: the studied present and promising future. Russian Journal of Clinical Ophthalmology. 2022;22(4):240–246 (in Russ.). DOI: 10.32364/2311-7729-2022- 22-4-240-246.","PeriodicalId":36455,"journal":{"name":"Russian Journal of Clinical Ophthalmology","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Clinical Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2311-7729-2022-22-4-240-246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Age-related macular degeneration (AMD) is the main cause of central vision loss in elder group of patients. At the same time, annually, the number of people with detected changes in the retina corresponding to different forms of macular dystrophy is steadily growing. The disease is considered to be a highly significant medical, social and economic problem, since a deterioration of the central vision negatively affects the life quality and work capacity of patients. The article presents an analysis of modern views concerning the current therapy possibilities for the dry form of AMD, including the use of nutraceuticals, consisting of lutein, zeaxanthin, mesoseaxanthin, as well as an overview of the directions of development and clinical trials. The use of lutein- and zeaxanthin-containing compounds can be recommended for prevention both the AMD progression and the presence of risk factors for its development, especially in persons over 50 years of age, as well as in the presence of high visual workload. Keywords: age-related macular degeneration, nutraceuticals, carotenoids, lutein, zeaxanthin, mesoseaxanthin. For citation: Glazko N.G., Kanaeva O.A., Rabadanova M.H. Treatment of the dry form of age-related macular degeneration: the studied present and promising future. Russian Journal of Clinical Ophthalmology. 2022;22(4):240–246 (in Russ.). DOI: 10.32364/2311-7729-2022- 22-4-240-246.

查看原文本刊更多论文

干型老年性黄斑变性的治疗:研究现状和前景

老年性黄斑变性(AMD)是导致中枢性视力丧失的主要原因。与此同时，每年发现视网膜变化与不同形式的黄斑营养不良相对应的人数正在稳步增长。这种疾病被认为是一个非常严重的医疗、社会和经济问题，因为中央视力的恶化会对患者的生活质量和工作能力产生负面影响。本文分析了目前干性黄斑变性的治疗方法，包括叶黄素、玉米黄质、中海黄质等营养药品的使用，并对其发展方向和临床试验进行了概述。可以推荐使用含有叶黄素和玉米黄质的化合物来预防AMD的进展及其发展的危险因素，特别是在50岁以上的人群中，以及在存在高视力负荷的情况下。关键词:老年性黄斑变性，营养品，类胡萝卜素，叶黄素，玉米黄质，中膜黄质。引文:Glazko n.g.， Kanaeva O.A, Rabadanova M.H.干型老年性黄斑变性的治疗:研究的现状和前景。俄罗斯临床眼科杂志。2022;22(4):240-246(俄文)。Doi: 10.32364/2311-7729-2022- 22-4-240-246。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊